Unknown

Dataset Information

0

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.


ABSTRACT: BACKGROUND:With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES). METHODS:Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ?4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT00044304: registered at clinicaltrials.gov). The primary outcome was an eosinophil count <1.5 × 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. A retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily ? 1 month) were classified according to the criteria used in the prospective study. RESULTS:Overall, imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of ? 4 myeloid features was the sole predictor of response. After ? 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remain in remission off therapy for a median of 29 months (range 14-36). CONCLUSIONS:Clinical features of MHES predict imatinib response in PDGFRA-negative HES.

SUBMITTER: Khoury P 

PROVIDER: S-EPMC6109366 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.

Khoury P P   Desmond R R   Pabon A A   Holland-Thomas N N   Ware J M JM   Arthur D C DC   Kurlander R R   Fay M P MP   Maric I I   Klion A D AD  

Allergy 20160302 6


<h4>Background</h4>With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES).<h4>Methods</h4>Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy (NCT0004  ...[more]

Similar Datasets

| S-EPMC5760470 | biostudies-other
| S-EPMC6557265 | biostudies-literature
| S-EPMC5963242 | biostudies-literature
| S-EPMC2801956 | biostudies-literature
| S-EPMC7175807 | biostudies-literature
| S-EPMC8636825 | biostudies-literature
| S-EPMC9270668 | biostudies-literature
| S-EPMC8478239 | biostudies-literature
| S-EPMC3418460 | biostudies-literature
| S-EPMC4520639 | biostudies-literature